The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Blueprint Medicines announced independent centrally reviewed top-line data for pralsetinib in patients with RET fusion-positive non-small cell lung ...
read more
Mercaptor Discoveries announced the advancement of its preclinical program in epilepsy.
read more
Tyme Technologies announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial for the third-line ...
read more
Sinovac Biotech announced the China NMPA has approved and issued a Product license for the Company’s varicella vaccine to prevent the chickenpox in ...
read more
Pulmatrix has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson.
read more
Thursday, January 02, 2020
FDA, AstraZeneca Pharmaceuticals
The FDA has approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic ...
read more
Thursday, January 02, 2020
DUR-928 did not demonstrate a benefit over vehicle (placebo) based on IGA, which was the scoring system for the primary analysis, or in any of the ...
read more
Monday, December 23, 2019
Catalyst Biosciences has entered into a global license and collaboration agreement with Biogen for the development and commercialization of pegylated ...
read more
Monday, December 23, 2019
The FDA granted accelerated approval to Enhertu for unresectable or metastatic HER2-positive breast cancer.
read more
Monday, December 23, 2019
Sosei Group has been notified by Pfizer it has dosed the first subject in a clinical trial with a new drug candidate nominated from the multi-target ...
read more
Monday, December 23, 2019
Urovant Sciences announced the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902.
read more
Monday, December 23, 2019
The FDA has approved two applications for the first generics of Eliquis tablets to reduce the risk of stroke and systemic embolism in patients with ...
read more
Friday, December 20, 2019
Amgen and Allergan announced the submission of a BLA to the FDA for ABP 798, a biosimilar candidate to Rituxan® (rituximab).
read more
Friday, December 20, 2019
Rezolute announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and ...
read more
Friday, December 20, 2019
Ionis announced Biogen has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of MAPT in the central nervous system...
read more